Panic disorder and chest pain in the coronary care unit. Psychosomatics. 1992;33:302 9. 58. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999;281:707 13. 59. Rouan GW, Lee TH, Cook EF, et al. Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspe- cific electrocardiograms (a report from the Multicenter Chest Pain Study). Am J Cardiol. 1989;64:1087 92. 60. McCarthy BD, Wong JB, Selker HP. Detecting acute cardiac ischemia in the emergency department: a review of the literature. J Gen Intern Med. 1990;5:365 73. 61. Slater DK, Hlatky MA, Mark DB, et al. Outcome in suspected acute myo- cardial infarction with normal or minimally abnormal admission electro- cardiographic findings. Am J Cardiol. 1987;60:766 70. 62. Lev EI, Battler A, Behar S, et al. Frequency, characteristics, and outcome of patients hospitalized with acute coronary syndromes with undetermined electrocardiographic patterns. Am J Cardiol. 2003;91:224 7. 63. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocar- dial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361:858 67. 64. Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin I assayandearlydiagnosisofmyocardialinfarction.JAMA.2011;306:2684 93. 65. Than M, Cullen L,Aldous S, et al. 2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. J Am Coll Cardiol. 2012;59:2091 8. 66. Goldstein JA, Chinnaiyan KM, Abidov A, et al. The CT-STAT (Coronary ComputedTomographicAngiographyforSystematicTriageofAcuteChest Pain Patients to Treatment) trial. J Am Coll Cardiol. 2011;58:1414 22. 67. Eggers KM, Jaffe AS, Venge P, et al. Clinical implications of the change of cardiac troponin I levels in patients with acute chest pain - an evalua- tion with respect to the Universal Definition of Myocardial Infarction. Clin Chim Acta. 2011;412:91 7. 68. Giannitsis E, Becker M, Kurz K, et al. High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and nega- tive troponin results on admission. Clin Chem. 2010;56:642 50. 69. Lindahl B, Venge P, James S. The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes. Am Heart J. 2010;160:224 9. 70. Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation. 2011;124:136 45. 71. Apple FS, Smith SW, Pearce LA, et al. Delta changes for optimizing clini- cal specificity and 60-day risk of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome utilizing the ADVIA Centaur Tnl-Ultra assay. Clin Biochem. 2012;45:711 3. 72. Santalo M, Martin A, Velilla J, et al. Using high-sensitivity troponin T: the importance of the proper gold standard. Am J Med. 2013;126:709 17. 73. Apple FS, Pearce LA, Smith SW, et al. Role of monitoring changes in sensi- tive cardiac troponin I assay results for early diagnosis of myocardial infarc- tion and prediction of risk of adverse events. Clin Chem. 2009;55:930 7. 74. Hammarsten O, Fu ML, Sigurjonsdottir R, et al. Troponin T percentiles from a random population sample, emergency room patients and patients with myocardial infarction. Clin Chem. 2012;58:628 37. 75. Pollack CV Jr., Sites FD, Shofer FS, et al. Application of the TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome to an unselected emergency department chest pain population. Acad Emerg Med. 2006;13:13 8. 76. Go J, Narmi A, Sype J, et al. Impact of renal dysfunction on the prognostic value of the TIMI risk score in patients with non-ST elevation acute coro- nary syndrome. Coron Artery Dis. 2011;22:411 5. 77. Huynh T, Nasmith J, Luong TM, et al. Complementary prognostic val- ues of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: Insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Can J Cardiol. 2009;25:e417 21. 78. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month post- discharge death in an international registry. JAMA. 2004;291:2727 33. 79. Abu-Assi E, Ferreira-Gonzalez I, Ribera A, et al. Do GRACE (Global Registry of Acute Coronary events) risk scores still maintain their perfor- mance for predicting mortality in the era of contemporary management of acute coronary syndromes? . Am Heart J. 2010;160:826 34. 80. Meune C, Drexler B, Haaf P, et al. The GRACE score s performance in pre- dicting in-hospital and 1-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide. Heart. 2011;97:1479 83. 81. Eggers KM, Kempf T, Venge P, et al. Improving long-term risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomark- ers. Am Heart J. 2010;160:88 94. 82. Matetzky S, Freimark D, Feinberg MS, et al. Acute myocardial infarction with isolated ST-segment elevation in posterior chest leads V7-9: hid- den ST-segment elevations revealing acute posterior infarction. J Am Coll Cardiol. 1999;34:748 53. 83. Boden WE, Kleiger RE, Gibson RS, et al. Electrocardiographic evolution of posterior acute myocardial infarction: importance of early precordial ST-segment depression. Am J Cardiol. 1987;59:782 7. 84. Zalenski RJ, Rydman RJ, Sloan EP, et al. Value of posterior and right ven- tricular leads in comparison to the standard 12-lead electrocardiogram in evaluation of ST-segment elevation in suspected acute myocardial infarc- tion. Am J Cardiol. 1997;79:1579 85. 85. Selker HP, Zalenski RJ, Antman EM, et al. An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: a report from a National Heart Attack Alert Program Working Group. Ann Emerg Med. 1997;29:13 87. 86. Fesmire FM, Percy RF, Bardoner JB, et al. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain. Ann Emerg Med. 1998;31:3 11. 87. Haaf P, Reichlin T, Corson N, et al. B-type natriuretic peptide in the early diagnosis and risk stratification of acute chest pain. Am J Med. 2011;124:444 52. 88. Brown AM, Sease KL, Robey JL, et al. The impact of B-type natriuretic peptide in addition to troponin I, creatine kinase-MB, and myoglobin on the risk stratification of emergency department chest pain patients with potential acute coronary syndrome. Ann Emerg Med. 2007;49:153 63. 89. Heeschen C, Hamm CW, Mitrovic V, et al. N-terminal pro-B-type natri- uretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110:3206 12. 90. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natri- uretic peptide for risk assessment in unstable angina/non-ST-elevation myocardialinfarction:B-typenatriureticpeptideandprognosisinTACTICS- TIMI 18. J Am Coll Cardiol. 2003;41:1264 72. 91. James SK, Lindback J, Tilly J, et al. Troponin-T and N-terminal pro-B- type natriuretic peptide predict mortality benefit from coronary revascu- larization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol. 2006;48:1146 54. 92. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. 1998;339:436 43. 93. Effects of tissue plasminogen activator and a comparison of early inva- sive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation. 1994;89:1545 56. 94. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myo- cardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998;338:1488 97. 95. Chang WC, Boersma E, Granger CB, et al. Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. Am Heart J. 2004;148:62 71. 96. Ronner E, Boersma E, Laarman GJ, et al. Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. J Am Coll Cardiol. 2002;39:1924 9. 97. Theroux P, Alexander JJ, Pharand C, et al. Glycoprotein IIb/IIIa recep- tor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation. 2000;102:2466 72. 98. Zhao XQ, Theroux P, Snapinn SM, et al. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syn- drome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation. 1999;100:1609 15. 99. BraunwaldE.Unstableangina.Aclassification.Circulation.1989;80:410 4. 100. Chaitman BR, Bourassa MG, Davis K, et al Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). Circulation. 1981;64:360 7. 101. Pryor DB, Harrell FE Jr., Lee KL, et al. Estimating the likelihood of significant coronary artery disease. Am J Med. 1983;75:771 80. 102. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med. 1993;118:81 90. 103. Morise AP, Haddad WJ, Beckner D. Development and validation of a clinical score to estimate the probability of coronary artery disease in men and women presenting with suspected coronary disease. Am J Med. 1997;102:350 6. 104. Ho KT, Miller TD, Hodge DO, et al. Use of a simple clinical score to predict prognosis of patients with normal or mildly abnormal resting Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e397 electrocardiographic findings undergoing evaluation for coronary artery disease. Mayo Clin Proc. 2002;77:515 21. 105. Kasser IS, Bruce RA. Comparative effects of aging and coronary heart dis- ease on submaximal and maximal exercise. Circulation. 1969;39:759 74. 106. Fraker TD Jr., Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation. 2007;116:2762 72. 107. Abidov A, Rozanski A, Hachamovitch R, et al. Prognostic significance of dyspnea in patients referred for cardiac stress testing. N Engl J Med. 2005;353:1889 98. 108. Patel H, RosengrenA, Ekman I. Symptoms in acute coronary syndromes: does sex make a difference? Am Heart J. 2004;148:27 33. 109. McSweeney JC, Cody M, O Sullivan P, et al. Women s early warning symptoms of acute myocardial infarction. Circulation. 2003;108:2619 23. 110. Lee TH, Cook EF, Weisberg M, et al. Acute chest pain in the emergency room. Identification and examination of low-risk patients. Arch Intern Med. 1985;145:65 9. 111. Pozen MW, D Agostino RB, Selker HP, et al. A predictive instrument to improve coronary-care-unit admission practices in acute ischemic heart dis- ease.Aprospectivemulticenterclinicaltrial.NEnglJMed.1984;310:1273 8. 112. Selker HP, Griffith JL, D Agostino RB. A tool for judging coronary care unit admission appropriateness, valid for both real-time and retrospec- tive use. A time-insensitive predictive instrument (TIPI) for acute cardiac ischemia: a multicenter study. Med Care. 1991;29:610 27. 113. Henrikson CA, Howell EE, Bush DE, et al. Chest pain relief by nitro- glycerin does not predict active coronary artery disease. Ann Intern Med. 2003;139: 979 86. 114. Swap CJ, Nagurney JT. Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. JAMA. 2005;294:2623 9. 115. Brieger DB, Mak KH, White HD, et al. Benefit of early sustained reper- fusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. Am J Cardiol. 1998;81:282 7. 116. Mega JL, Hochman JS, Scirica BM, et al. Clinical features and outcomes of women with unstable ischemic heart disease: observations from meta- bolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36). Circulation. 2010;121:1809 17. 117. Holmes DR Jr., White HD, Pieper KS, et al. Effect of age on outcome with primary angioplasty versus thrombolysis. J Am Coll Cardiol. 1999;33:412 9. 118. White HD, Barbash GI, Califf RM, et al. Age and outcome with con- temporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation. 1996;94:1826 33. 119. Michos ED, Vasamreddy CR, Becker DM, et al. Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. Am Heart J. 2005;150:1276 81. 120. Tadros GM, McConnell TR, Wood GC, et al. Clinical predictors of 30-day cardiac events in patients with acute coronary syndrome at a com- munity hospital. South Med J. 2003;96:1113 20. 121. Nasir K, Michos ED, Rumberger JA, et al. Coronary artery calcifica- tion and family history of premature coronary heart disease: sibling history is more strongly associated than parental history. Circulation. 2004;110:2150 6. 122. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mel- litus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1997;30:171 9. 123. Mehta RH, Califf RM, Garg J, et al. The impact of anthropomorphic indi- ces on clinical outcomes in patients with acute ST-elevation myocardial infarction. Eur Heart J. 2007;28:415 24. 124. Nigam A, Wright RS, Allison TG, et al. Excess weight at time of presen- tation of myocardial infarction is associated with lower initial mortality risks but higher long-term risks including recurrent re-infarction and car- diac death. Int J Cardiol. 2006;110:153 9. 125. Diercks DB, Roe MT, Mulgund J, et al. The obesity paradox in non-ST- segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients SuppressADverse outcomes with Early implementation of the American College of Cardiology/ American Heart Association Guidelines Quality Improvement Initiative. Am Heart J. 2006;152:140 8. 126. Rubinshtein R, Halon DA, Jaffe R, et al. Relation between obesity and severity of coronary artery disease in patients undergoing coronary angi- ography. Am J Cardiol. 2006;97:1277 80. 127. Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women. N Engl J Med. 2006;355:779 87. 128. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mor- tality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355:763 78. 129. Romero-Corral A, Montori VM, Somers VK, et al. Association of body- weight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368: 666 78. 130. Mittleman MA, Mintzer D, Maclure M, et al. Triggering of myocardial infarction by cocaine. Circulation. 1999;99:2737 41. 131. Turnipseed SD, Richards JR, Kirk JD, et al. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med. 2003;24:369 73. 132. McCord J, Jneid H, Hollander JE, et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from theAmerican Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation. 2008;117:1897 907. 133. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular- weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447 52. 134. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet. 2001;358:1571 5. 135. Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2005;46:906 19. 136. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myo- cardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593 601. 137. Morrow DA, Antman EM, Snapinn SM, et al. An integrated clini- cal approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/ NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23: 223 9. 138. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879 87. 139. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360:2165 75. 140. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarc- tion: results from a randomized trial. JAMA. 2001;286:2405 12. 141. O Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs con- servative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008;300:71 80. 142. Deleted in press. 143. Brush JE Jr., Brand DA, Acampora D, et al. Use of the initial electrocar- diogram to predict in-hospital complications of acute myocardial infarc- tion. N Engl J Med. 1985;312:1137 41. 144. Fesmire FM, Percy RF, Wears RL, et al. Risk stratification according to the initial electrocardiogram in patients with suspected acute myocardial infarction. Arch Intern Med. 1989;149:1294 7. 145. Fesmire FM, Percy RF, Wears RL. Diagnostic and prognostic importance of comparing the initial to the previous electrocardiogram in patients admitted for suspected acute myocardial infarction. South Med J. 1991;84:841 6. 146. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998;97:1195 206. 147. Jaffe AS. The 10 commandments of troponin, with special reference to high sensitivity assays. Heart. 2011;97:940 6. 148. de Zwaan, Bar FW, Janssen JH, et al. Angiographic and clinical charac- teristics of patients with unstable angina showing an ECG pattern indicat- ing critical narrowing of the proximal LAD coronary artery. Am Heart J. 1989;117:657 65. 149. Haines DE, Raabe DS, Gundel WD, et al. Anatomic and prognostic significance of new T-wave inversion in unstable angina. Am J Cardiol. 1983;52:14 8. 150. Hochman JS, Sleeper LA, Godfrey E, et al. SHould we emergently revas- cularize Occluded Coronaries for cardiogenic shocK: an international randomized trial of emergency PTCA/CABG-trial design. The SHOCK Trial Study Group. Am Heart J. 1999;137:313 21. 151. Holmes DR Jr., Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation. 1999;100:2067 73. 152. Kavsak PA, MacRae AR, Lustig V, et al. The impact of the ESC/ ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction. Am Heart J. 2006;152:118 25. 153. Goodman SG, Steg PG, Eagle KA, et al. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2006;151:654 60. 154. Amodio G, Antonelli G, Varraso L, et al. Clinical impact of the troponin 99th percentile cut-off and clinical utility of myoglobin measurement in the early management of chest pain patients admitted to the Emergency Cardiology Department. Coron Artery Dis. 2007;18:181 6. 155. Takakuwa KM, Ou FS, Peterson ED, et al. The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST- segment elevation acute coronary syndrome: results from CRUSADE. Clin Cardiol. 2009;32:498 505. 156. Ie EH, Klootwijk PJ, Weimar W, et al. Significance of acute versus chronic troponin T elevation in dialysis patients. Nephron Clin Pract. 2004;98:c87 92. 157. MacRae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour interval between specimens in theAmerican HeartAssociation Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem. 2006;52:812 8. 158. Kontos MC, de Lemos JA, Ou FS, et al. Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: an undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. Am Heart J. 2010;160:819 25. 159. Aviles RJ,Wright RS,Aviles JM, et al. Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin i levels. Am J Cardiol. 2002;90:875 8. 160. Eggers KM, Oldgren J, Nordenskjold A, et al. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J. 2004;148:574 81. 161. Volz KA, McGillicuddy DC, Horowitz GL, et al. Creatine kinase-MB does not add additional benefit to a negative troponin in the evaluation of chest pain. Am J Emerg Med. 2012;30:188 90. 162. Newby LK, Roe MT, Chen AY, et al. Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol. 2006;47:312 8. 163. Kavsak PA, MacRae AR, Newman AM, et al. Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocar- dial infarction. Clin Chim Acta. 2007;380:213 6. 164. Giannitsis E, Steen H, Kurz K, et al. Cardiac magnetic resonance imag- ing study for quantification of infarct size comparing directly serial ver- sus single time-point measurements of cardiac troponin T. J Am Coll Cardiol. 2008;51:307 14. 165. Younger JF, Plein S, Barth J, et al. Troponin-I concentration 72 h after myocardial infarction correlates with infarct size and presence of micro- vascular obstruction. Heart. 2007;93:1547 51. 166. Bonaca M, Scirica B, Sabatine M, et al. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol. 2010;55:2118 24. 167. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014 21. 168. Weber M, Bazzino O, Navarro Estrada JL, et al. N-terminal B-type natri- uretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. J Am Coll Cardiol. 2008;51:1188 95. 169. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 2000;35:1535 42. 170. Kilcullen N, Viswanathan K, Das R, et al. Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardiol. 2007;50:2061 7. 171. Wollert KC, Kempf T, Lagerqvist B, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007;116:1540 8. 172. Roger VL, Killian JM, Weston SA, et al. Redefinition of myocardial infarc- tion:prospectiveevaluationinthecommunity.Circulation.2006;114:790 7. 173. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity car- diac troponin assays. J Am Coll Cardiol. 2013;61:1753 8. 174. Eggers KM, Lind L, Venge P, et al. Will the universal definition of myo- cardial infarction criteria result in an overdiagnosis of myocardial infarc- tion? Am J Cardiol. 2009;103:588 91. 175. Bonaca MP, Wiviott SD, Braunwald E, et al. American College of Cardiology/American HeartAssociation/European Society of Cardiology/ World Heart Federation universal definition of myocardial infarction clas- sification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitionWith Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation. 2012;125:577 83. 176. Sabatine MS, Morrow DA, de Lemos JA, et al. Detection of acute changes in circulating troponin in the setting of transient stress test- induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J. 2009;30:162 9. 177. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503 12. 178. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponinmeasurementinacutecardiaccare.EurHeartJ.2010;31:2197 204. 179. Westgard J, Klee G. Quality management. In: Burtris C, Ashwood E, Bruns D, editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. St Louis, MO: Elsevier/Saunders, 2006:498 9. 180. Freda BJ,TangWH,Van LF, et al. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol. 2002;40:2065 71. 181. Meune C, Balmelli C,Twerenbold R, et al. Patients with acute coronary syn- drome and normal high-sensitivity troponin. Am J Med. 2011;124:1151 7. 182. Apple FS, Murakami MM, Pearce LA, et al. Predictive value of car- diac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002; 106:2941 5. 183. Apple FS, Jesse RL, Newby LK, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007;53:547 51. 184. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity car- diac troponins in acute cardiac care. Eur Heart J. 2012;33:2252 7. 185. SandovalY, Apple FS. The global need to define normality: the 99th per- centile value of cardiac troponin. Clin Chem. 2014;60:455 62. 186. Fleming SM, O Gorman T, Finn J, et al. Cardiac troponin I in pre- eclampsia and gestational hypertension. BJOG. 2000;107:1417 20. 187. Yang X, Wang H, Wang Z, et al. Alteration and significance of serum cardiac troponin I and cystatin C in preeclampsia. Clin Chim Acta. 2006;374:168 9. 188. Joyal D, Leya F, Koh M, et al. Troponin I levels in patients with pre- eclampsia. Am J Med. 2007;120:819. 189. Aydin C, BalogluA, Cetinkaya B, et al. Cardiac troponin levels in pregnant women with severe preeclampsia. J Obstet Gynaecol. 2009;29:621 3. 190. Diercks DB, Peacock WF, Hollander JE, et al. Diagnostic accuracy of a point-of-care troponin I assay for acute myocardial infarction within 3 hours after presentation in early presenters to the emergency department with chest pain. Am Heart J. 2012;163:74 80. 191. van Domburg RT, Cobbaert C, Kimman GJ, et al. Long-term prognostic value of serial troponin T bedside tests in patients with acute coronary syndromes. Am J Cardiol. 2000;86:623 7. 192. Venge P, Ohberg C, Flodin M, et al. Early and late outcome prediction of death in the emergency room setting by point-of-care and laboratory assays of cardiac troponin I. Am Heart J. 2010;160:835 41. 193. Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to thera- peutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet. 1999;354:1757 62. Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e399 194. Lindahl B, Diderholm E, Lagerqvist B, et al. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol. 2001;38:979 86. 195. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295:1531 8. 196. Apple FS, Christenson RH, Valdes R Jr., et al. Simultaneous rapid mea- surement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarc- tion. Clin Chem. 1999;45:199 205. 197. Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-ele- vation acute coronary syndromes. J Am Coll Cardiol. 2002;40:1044 50. 198. Storrow AB, Lindsell CJ, Han JH, et al. Discordant cardiac biomarkers: frequency and outcomes in emergency department patients with chest pain. Ann Emerg Med. 2006;48:660 5. 199. Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med. 2002;346: 2047 52. 200. Farkouh ME, Smars PA, Reeder GS, et al. A clinical trial of a chest- pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators. N Engl J Med. 1998;339:1882 8. 201. Gomez MA, Anderson JL, Karagounis LA, et al. An emergency depart- ment-based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: results of a randomized study (ROMIO). JAm Coll Cardiol. 1996;28:25 33. 202. Amsterdam EA, Kirk JD, Diercks DB, et al. Immediate exercise test- ing to evaluate low-risk patients presenting to the emergency department with chest pain. J Am Coll Cardiol. 2002;40:251 6. 203. Trippi JA, Lee KS. Dobutamine stress tele-echocardiography as a clinical service in the emergency department to evaluate patients with chest pain. Echocardiography. 1999;16:179 85. 204. Bholasingh R, Cornel JH, Kamp O, et al. Prognostic value of predis- charge dobutamine stress echocardiography in chest pain patients with a negative cardiac troponin T. J Am Coll Cardiol. 2003;41:596 602. 205. Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiog- raphy versus standard evaluation in acute chest pain. N Engl J Med. 2012;367:299 308. 206. Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med. 2012;366:1393 403. 207. Hoffmann U, Bamberg F, Chae CU, et al. Coronary computed tomog- raphy angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol. 2009;53:1642 50. 208. Udelson JE, Beshansky JR, Ballin DS, et al. Myocardial perfusion imag- ing for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. JAMA. 2002;288:2693 700. 209. Kontos MC, Jesse RL, Schmidt KL, et al. Value of acute rest sestamibi perfusion imaging for evaluation of patients admitted to the emergency department with chest pain. J Am Coll Cardiol. 1997;30:976 82. 210. Than M, Cullen L, Reid CM, et al. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet. 2011;377:1077 84. 211. Gibbons RJ. Chest pain triage in the ED: is CT coronary angiography the answer? J Nucl Cardiol. 2012;19:404 6. 212. Anderson JL,Adams CD,Antman EM, et al.ACC/AHA 2007 guidelines for themanagementofpatientswithunstableangina/nonST-elevationmyocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/ Non ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148 304. 213. Farquhar H, Weatherall M, Wijesinghe M, et al. Systematic review of studies of the effect of hyperoxia on coronary blood flow. Am Heart J. 2009;158:371 7. 214. Cabello JB, Burls A, Emparanza JI, et al. Oxygen therapy for acute myo- cardial infarction. Cochrane Database Syst Rev. 2010:CD007160. 215. Moradkhan R, Sinoway LI. Revisiting the role of oxygen therapy in car- diac patients. J Am Coll Cardiol. 2010;56:1013 6. 216. Goldstein RE, Rosing DR, Redwood DR, et al. Clinical and circulatory effects of isosorbide dinitrate. Comparison with nitroglycerin. Circulation. 1971;43:629 40. 217. Bassan MM. The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate. J Am Coll Cardiol. 1990;16:936 40. 218. Kohli RS, Rodrigues EA, Kardash MM, et al. Acute and sustained effects of isosorbide 5-mononitrate in stable angina pectoris. Am J Cardiol. 1986;58:727 31. 219. Kaplan K, Davison R, Parker M, et al. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy. Am J Cardiol. 1983;51:694 8. 220. Melandri G, Branzi A, Tartagni F, et al. Haemodynamic effects of meto- prolol and intravenous nitroglycerin versus metoprolol alone in patients with acute myocardial infarction. Eur Heart J. 1987;8:592 6. 221. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet. 1988;1:1088 92. 222. Charvat J, Kuruvilla T, al AH. Beneficial effect of intravenous nitro- glycerin in patients with non-Q myocardial infarction. Cardiologia. 1990;35:49 54. 223. Karlberg KE, Saldeen T, Wallin R, et al. Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: a double-blind placebo- controlled study. J Intern Med. 1998;243:25 31. 224. Peacock WF, Emerman CL, Young J. Nesiritide in congestive heart fail- ure associated with acute coronary syndromes: a pilot study of safety and efficacy. J Card Fail. 2004;10:120 5. 225. Cheitlin MD, Hutter AM Jr., Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation. 1999;99:168 77. 226. Webb DJ, Freestone S,Allen MJ, et al. Sildenafil citrate and blood-pressure- lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol. 1999;83:21C 8C. 227. Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003;42:1855 60. 228. Knight CJ, Panesar M, Wilson DJ, et al. Different effects of cal- cium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation. 1997;95:125 32. 229. Mahmarian JJ, Moye LA, Chinoy DA, et al.Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective random- ized, double-blind, placebo-controlled trial. Circulation. 1998;97:2017 24. 230. Garcia-Dorado D, Permanyer-Miralda G, Brotons C, et al. Attenuated severity of new acute ischemic events in patients with previous coronary heart disease receiving long-acting nitrates. Clin Cardiol. 1999;22:303 8. 231. Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and car- diovascular disease: a scientific statement from the American Heart Association. Circulation. 2012;125:1058 72. and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149:1043 9. 233. Iakobishvili Z, Cohen E, Garty M, et al. Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes. Acute Card Care. 2011;13:76 80. 234. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarc- tion associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906 13. 235. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302 8. 236. Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008;25:205 9. 237. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiin- flammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634 42. 238. Gibson CM, Pride YB, Aylward PE, et al. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. J Thromb Thrombolysis. 2009;27:11 7. 239. Becker MC, Wang TH, Wisniewski L, et al. Rationale, design, and gov- ernance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157:606 12. 240. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422 37. 241. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocar- dial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730 7. 242. Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker ther- apy: results from the American College of Cardiology s NCDR((R)). Am Heart J. 2011;161:864 70. 243. de Peuter OR, Lussana F, Peters RJ, et al. A systematic review of selec- tive and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med. 2009;67:284 94. 244. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral meto- prolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622 32. 245. Ryden L, Ariniego R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med. 1983;308:614 8. 246. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385 90. 247. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post- Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45:525 30. 248. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double- blind, randomized, multicenter trial. N Engl J Med. 1986;315:423 9. 249. Effect of verapamil on mortality and major events after acute myocar- dial infarction (the Danish Verapamil Infarction Trial II DAVIT II). Am J Cardiol. 1990;66:779 85. 250. Moss AJ, Oakes D, Rubison M, et al. Effects of diltiazem on long- term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. The Multicenter Diltiazem Postinfarction Trial Research Group. Am J Cardiol. 1991; 68:429 33. 251. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mor- tality in patients with coronary heart disease. Circulation. 1995;92:1326 31. 252. Early treatment of unstable angina in the coronary care unit: a ran- domised, double blind, placebo controlled comparison of recurrent isch- aemia in patients treated with nifedipine or metoprolol or both. Report of the Holland Interuniversity Nifedipine/ Metoprolol Trial (HINT) Research Group. Br Heart J. 1986;56:400 13. 253. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronaryspasticangina)(JCS2008):digestversion.CircJ.2010;74:1745 62. 254. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with car- diovascular disease: an overview of randomized trials. Clin Cardiol. 1998;21:633 41. 255. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antago- nist reinfarction Italian study (CRIS). Am J Cardiol. 1996;77:365 9. 256. Smith NL, Reiber GE, Psaty BM, et al. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina. J Am Coll Cardiol. 1998;32:1305 11. 257. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group. Am J Cardiol. 1997;79:738 41. 258. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol. 1987;60:18A 25A. 259. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consen- sus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123:2434 506. 260. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina fre- quency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309 16. 261. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375 82. 262. Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113:2462 72. 263. Morrow DA, Scirica BM, Karwatowska- Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST- elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775 83. 264. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double- blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53:1510 6. 265. Stone GW, Ohman EM, Miller MF, et al. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol. 2003;41:1940 5. 266. Perera D, Stables R, Thomas M, et al. Elective intra-aortic balloon coun- terpulsation during high-risk percutaneous coronary intervention: a ran- domized controlled trial. JAMA. 2010;304:867 74. and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011;306:1329 37. 268. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon sup- port for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287 96. 269. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovas- cular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438 45. 270. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. 271. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moder- ate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495 504. 272. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001 9. 273. Cannon CP, McCabe CH, Belder R, et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 2002;89:860 1. 274. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711 8. 275. Garg R,Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450 6. 276. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145 53. 277. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricu- lar dysfunction, or both. N Engl J Med. 2003;349:1893 906. 278. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547 59. 279. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309 21. 280. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intol- erant to angiotensin-converting enzyme inhibitors: a randomised con- trolled trial. Lancet. 2008;372:1174 83. 281. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368:581 8. 282. Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long- term randomized controlled trials. Arch Intern Med. 2006;166:787 96. 283. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97:2202 12. 284. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e401 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669 85. 285. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortal- ity and morbidity in patients with left ventricular dysfunction after myo- cardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669 77. 286. Kaul P, Ezekowitz JA,Armstrong PW, et al. Incidence of heart failure and mortality after acute coronary syndromes.Am Heart J. 2013;165:379 85. 287. Rossignol P, Menard J, Fay R, et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58:1958 66. 288. Baigent C, Blackwell L, Collins R, et al.Aspirin in the primary and second- ary prevention of vascular disease: collaborative meta-analysis of individ- ual participant data from randomised trials. Lancet. 2009;373:1849 60. 289. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494 502. 290. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544 54. 291. CAPRIE Steering Committee. A randomised, blinded, trial of clopido- grel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329 39. 292. Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930 42. 293. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045 57. 294. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive man- agement: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011;342:d3527. 295. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatideinacutecoronarysyndromes.NEnglJMed.2009;360:2176 90. 296. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopi- dogrel and aspirin followed by long-term therapy in patients undergo- ing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527 33. 297. Ottervanger JP, Armstrong P, Barnathan ES, et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV Acute Coronary Syndrome) Trial. Circulation. 2003;107:437 42. 298. Berger JS, Sallum RH, Katona B, et al. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Am Heart J. 2012;164:153 62. 299. Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresis- tance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127:377 85. 300. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percu- taneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923 32. 301. Plaivx. Bristol-Myers Squibb: New York, NY. 2013. 302. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopi- dogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001 15. 303. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297 309. 304. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasu- grel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999 1010. 305. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32:2933 44. 306. AstraZeneca. Brilinta REMS document. NDA 22-433. 2011. 307. Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010;31:35 49. 308. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coro- nary syndromes: the ACUITY Timing trial. JAMA. 2007;297:591 602. 309. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfrac- tionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45 54. 310. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203 16. 311. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary interven- tion: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369:907 19. 312. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syn- dromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007;50:1742 51. 313. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparininacutecoronarysyndromes.NEnglJMed.2006;354:1464 76. 314. Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfrac- tionated heparin for percutaneous coronary intervention in acute coro- nary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304:1339 49. 315. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment eleva- tion myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519 30. 316. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811 5. 317. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105 11. 318. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery dis- ease. The RISC Group. Lancet. 1990;336:827 30. 319. Cohen M, Adams PC, Hawkins L, et al. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol. 1990;66:1287 92. 320. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy inAcute Coronary Syndromes Research Group. Circulation. 1994;89:81 8. 321. Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol. 1994;24:39 45. 322. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 1995;26:313 8. 323. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e24S 43S. 324. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol. 2000;36:693 8. 325. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfraction- ated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89 96. 326. White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006;152:1042 50. 327. Hochman JS, Wali AU, Gavrila D, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J. 1999;138:313 8. 328. Linkins LA, DansAL, Moores LK, et al. Treatment and prevention of hep- arin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141:e495S 530S. 329. Indications for fibrinolytic therapy in suspected acute myocardial infarc- tion: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Lancet. 1994;343:311 22. 330. Shishehbor MH, Topol EJ, Mukherjee D, et al. Outcome of multivessel coronary intervention in the contemporary percutaneous revasculariza- tion era. Am J Cardiol. 2006;97:1585 90. 331. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411 20. 332. Boden WE, O Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 1998;338:1785 92. 333. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353:1095 104. 334. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST- elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002;360:743 51. 335. McCullough PA, O Neill WW, Graham M, et al. A prospective random- ized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in throm- bolytic exclusion (MATE) trial. J Am Coll Cardiol. 1998;32:596 605. 336. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of pro- longed antithrombotic pretreatment ( cooling-off strategy) before inter- vention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003;290:1593 9. 337. Spacek R, Widimsky P, Straka Z, et al. Value of first day angiography/ angioplasty in evolving Non-ST segment elevation myocardial infarc- tion: an open multicenter randomized trial. The VINO Study. Eur Heart J. 2002;23:230 8. 338. Damman P, Hirsch A, Windhausen F, et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coro- nary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010;55:858 64. 339. Invasive compared with non-invasive treatment in unstable coronary- artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999;354:708 15. 340. Fox KA, Clayton TC, Damman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment eleva- tion acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010;55:2435 45. 341. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strat- egies in patients with acute coronary syndromes: a collaborative meta- analysis of randomized trials. JAMA. 2005;293:2908 17. 342. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interven- tional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. 2005;366:914 20. 343. Navarese EP, Gurbel PA, Andreotti F, et al. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis.Ann Intern Med. 2013;158:261 70. 344. Lagerqvist B, Safstrom K, Stahle E, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol. 2001;38:41 8. 345. Dolor RJ, Melloni C, Chatterjee R, et al. Treatment strategies for women with coronary artery disease. Comparative effectiveness review no. 66. Rockville, MD: Agency for healthcare Research and Quality. 2012. AHRQ publication no. 12-EHC070-EF. Available at: http://www.effectivehealthcare.ahrq.gov/ reports/final.cfm.Accessed July 30, 2014. 346. Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002;288: 3124 9. 347. O Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012;60:106 11. 348. Raman SV, Simonetti OP, Winner MW III, et al. Cardiac magnetic reso- nance with edema imaging identifies myocardium at risk and predicts worse outcome in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010;55:2480 8. 349. Starling MR, Crawford MH, Kennedy GT, et al. Treadmill exercise tests predischarge and six weeks post-myocardial infarction to detect abnor- malities of known prognostic value. Ann Intern Med. 1981;94:721 7. 350. Marwick TH, Anderson T, Williams MJ, et al. Exercise echocardiogra- phy is an accurate and cost-efficient technique for detection of coronary artery disease in women. J Am Coll Cardiol. 1995;26:335 41. 351. Larsson H, Areskog M, Areskog NH, et al. Should the exercise test (ET) be performed at discharge or one month later after an episode of unsta- ble angina or non-Q-wave myocardial infarction? Int J Card Imaging. 1991;7:7 14. 352. Nyman I, Larsson H,Areskog M, et al. The predictive value of silent isch- emia at an exercise test before discharge after an episode of unstable cor- onary artery disease. RISC Study Group. Am Heart J. 1992;123:324 31. 353. Mahmarian JJ, Shaw LJ, Filipchuk NG, et al. A multinational study to establish the value of early adenosine technetium-99m sestamibi myo- cardial perfusion imaging in identifying a low-risk group for early hos- pital discharge after acute myocardial infarction. J Am Coll Cardiol. 2006;48:2448 57. 354. Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation. 1998;98:1622 30. 355. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary inter- vention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121:2645 53. 356. Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J. 2011;32:2125 34. 357. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effec- tiveness of revascularization strategies. N Engl J Med. 2012;366:1467 76. 358. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass sur- gery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607 16. 359. Bangalore S, Faxon DP. Coronary intervention in patients with acute coronary syndrome: does every culprit lesion require revascularization? Curr Cardiol Rep. 2010;12:330 7. 360. Brener SJ, Milford-Beland S, Roe MT, et al. Culprit-only or multives- sel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. Am Heart J. 2008;155:140 6. 361. Brener SJ, Murphy SA, Gibson CM, et al. Efficacy and safety of multi- vessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. Am J Cardiol. 2002;90:631 3. 362. Palmer ND, Causer JP, Ramsdale DR, et al. Effect of completeness of revascularization on clinical outcome in patients with multivessel disease presenting with unstable angina who undergo percutaneous coronary intervention. J Invasive Cardiol. 2004;16:185 8. 363. Shishehbor MH, Lauer MS, Singh IM, et al. In unstable angina or non- ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? J Am Coll Cardiol. 2007;49:849 54. 364. Zapata GO, Lasave LI, Kozak F, et al. Culprit-only or multivessel per- cutaneous coronary stenting in patients with non-ST-segment elevation acute coronary syndromes: one-year follow-up. J Interv Cardiol. 2009; 22:329 35. 365. Chan PS, Patel MR, Klein LW, et al. Appropriateness of percutaneous coronary intervention. JAMA. 2011;306:53 61. 366. Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48:1319 25. 367. Hoenig MR, Doust JA, Aroney CN, et al. Early invasive versus conser- vative strategies for unstable angina and non-ST-elevation myocardial infarction in the stent era. 